Cargando…
Radioresistance in rhabdomyosarcomas: Much more than a question of dose
Management of rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, frequently accounting the genitourinary tract is complex and requires a multimodal therapy. In particular, as a consequence of the advancement in dose conformity technology, radiation therapy (RT) has now become t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559533/ https://www.ncbi.nlm.nih.gov/pubmed/36248991 http://dx.doi.org/10.3389/fonc.2022.1016894 |
_version_ | 1784807659555258368 |
---|---|
author | Camero, Simona Cassandri, Matteo Pomella, Silvia Milazzo, Luisa Vulcano, Francesca Porrazzo, Antonella Barillari, Giovanni Marchese, Cinzia Codenotti, Silvia Tomaciello, Miriam Rota, Rossella Fanzani, Alessandro Megiorni, Francesca Marampon, Francesco |
author_facet | Camero, Simona Cassandri, Matteo Pomella, Silvia Milazzo, Luisa Vulcano, Francesca Porrazzo, Antonella Barillari, Giovanni Marchese, Cinzia Codenotti, Silvia Tomaciello, Miriam Rota, Rossella Fanzani, Alessandro Megiorni, Francesca Marampon, Francesco |
author_sort | Camero, Simona |
collection | PubMed |
description | Management of rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, frequently accounting the genitourinary tract is complex and requires a multimodal therapy. In particular, as a consequence of the advancement in dose conformity technology, radiation therapy (RT) has now become the standard therapeutic option for patients with RMS. In the clinical practice, dose and timing of RT are adjusted on the basis of patients’ risk stratification to reduce late toxicity and side effects on normal tissues. However, despite the substantial improvement in cure rates, local failure and recurrence frequently occur. In this review, we summarize the general principles of the treatment of RMS, focusing on RT, and the main molecular pathways and specific proteins involved into radioresistance in RMS tumors. Specifically, we focused on DNA damage/repair, reactive oxygen species, cancer stem cells, and epigenetic modifications that have been reported in the context of RMS neoplasia in both in vitro and in vivo studies. The precise elucidation of the radioresistance-related molecular mechanisms is of pivotal importance to set up new more effective and tolerable combined therapeutic approaches that can radiosensitize cancer cells to finally ameliorate the overall survival of patients with RMS, especially for the most aggressive subtypes. |
format | Online Article Text |
id | pubmed-9559533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95595332022-10-14 Radioresistance in rhabdomyosarcomas: Much more than a question of dose Camero, Simona Cassandri, Matteo Pomella, Silvia Milazzo, Luisa Vulcano, Francesca Porrazzo, Antonella Barillari, Giovanni Marchese, Cinzia Codenotti, Silvia Tomaciello, Miriam Rota, Rossella Fanzani, Alessandro Megiorni, Francesca Marampon, Francesco Front Oncol Oncology Management of rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, frequently accounting the genitourinary tract is complex and requires a multimodal therapy. In particular, as a consequence of the advancement in dose conformity technology, radiation therapy (RT) has now become the standard therapeutic option for patients with RMS. In the clinical practice, dose and timing of RT are adjusted on the basis of patients’ risk stratification to reduce late toxicity and side effects on normal tissues. However, despite the substantial improvement in cure rates, local failure and recurrence frequently occur. In this review, we summarize the general principles of the treatment of RMS, focusing on RT, and the main molecular pathways and specific proteins involved into radioresistance in RMS tumors. Specifically, we focused on DNA damage/repair, reactive oxygen species, cancer stem cells, and epigenetic modifications that have been reported in the context of RMS neoplasia in both in vitro and in vivo studies. The precise elucidation of the radioresistance-related molecular mechanisms is of pivotal importance to set up new more effective and tolerable combined therapeutic approaches that can radiosensitize cancer cells to finally ameliorate the overall survival of patients with RMS, especially for the most aggressive subtypes. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9559533/ /pubmed/36248991 http://dx.doi.org/10.3389/fonc.2022.1016894 Text en Copyright © 2022 Camero, Cassandri, Pomella, Milazzo, Vulcano, Porrazzo, Barillari, Marchese, Codenotti, Tomaciello, Rota, Fanzani, Megiorni and Marampon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Camero, Simona Cassandri, Matteo Pomella, Silvia Milazzo, Luisa Vulcano, Francesca Porrazzo, Antonella Barillari, Giovanni Marchese, Cinzia Codenotti, Silvia Tomaciello, Miriam Rota, Rossella Fanzani, Alessandro Megiorni, Francesca Marampon, Francesco Radioresistance in rhabdomyosarcomas: Much more than a question of dose |
title | Radioresistance in rhabdomyosarcomas: Much more than a question of dose |
title_full | Radioresistance in rhabdomyosarcomas: Much more than a question of dose |
title_fullStr | Radioresistance in rhabdomyosarcomas: Much more than a question of dose |
title_full_unstemmed | Radioresistance in rhabdomyosarcomas: Much more than a question of dose |
title_short | Radioresistance in rhabdomyosarcomas: Much more than a question of dose |
title_sort | radioresistance in rhabdomyosarcomas: much more than a question of dose |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559533/ https://www.ncbi.nlm.nih.gov/pubmed/36248991 http://dx.doi.org/10.3389/fonc.2022.1016894 |
work_keys_str_mv | AT camerosimona radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT cassandrimatteo radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT pomellasilvia radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT milazzoluisa radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT vulcanofrancesca radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT porrazzoantonella radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT barillarigiovanni radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT marchesecinzia radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT codenottisilvia radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT tomaciellomiriam radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT rotarossella radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT fanzanialessandro radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT megiornifrancesca radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose AT maramponfrancesco radioresistanceinrhabdomyosarcomasmuchmorethanaquestionofdose |